ARTV

Artiva Biotherapeutics, Inc.
CAPPED RATING

Artiva Biotherapeutics, Inc. (ARTV) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.6
EV / EBITDA 1.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -66.1%
Price Return 12M 16.8%
Catalyst Signal 0.00
Market Cap $195.8M
TTM Revenue N/A
Price / Sales N/A
ROE -43.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) C+ (2.6) D (1.4) C- (1.9) F (0.0) C- (1.9)
2026-11-10 B+ (3.8) C (2.3) D (1.4) C- (2.1) F (0.0) C- (1.9)
2026-11-03 B+ (3.7) C (2.2) D (1.4) C- (1.9) F (0.0) D+ (1.8)
2026-10-27 B+ (3.7) D+ (1.7) D (1.4) D+ (1.8) C+ (2.6) C (2.2)
2026-10-20 B+ (3.7) D+ (1.7) D (1.4) C- (2.1) C+ (2.6) C (2.3)
Page 1 of 4